Actinogen Medical Ltd Asset Resilience Ratio
Actinogen Medical Ltd asset resilience ratio. Actinogen Medical Ltd (ACW) has an Asset Resilience Ratio of 74.78% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ACW cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Actinogen Medical Ltd (2016–2024)
Asset resilience ratio of Actinogen Medical Ltd from 2016 to 2024. This chart shows how Actinogen Medical Ltd's Asset Resilience Ratio has changed over time. Read Actinogen Medical Ltd total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Actinogen Medical Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Actinogen Medical Ltd total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$19.02 Million | 74.78% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$19.02 Million | 74.78% |
Asset Resilience Insights
- Very High Liquidity: Actinogen Medical Ltd maintains exceptional liquid asset reserves at 74.78% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Actinogen Medical Ltd Industry Peers by Asset Resilience Ratio
Compare Actinogen Medical Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 15.21% |
|
Abivax SA
PA:ABVX |
Biotechnology | 2.58% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Sinocelltech Group Ltd
SHG:688520 |
Biotechnology | 5.27% |
|
Inner Mongolia Furui Med Sci
SHE:300049 |
Biotechnology | 1.75% |
|
Mineralys Therapeutics, Inc. Common Stock
NASDAQ:MLYS |
Biotechnology | 78.33% |
|
GH Research PLC
NASDAQ:GHRS |
Biotechnology | 4.73% |
Actinogen Medical Ltd Asset Resilience Ratio by Year (2016–2024)
Actinogen Medical Ltd asset resilience ratio by year from 2016 to 2024. The table below shows the annual Asset Resilience Ratio data for Actinogen Medical Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-06-30 | 33.86% | AU$7.22 Million ≈ $5.11 Million |
AU$21.31 Million ≈ $15.08 Million |
-13.35pp |
| 2023-06-30 | 47.21% | AU$7.18 Million ≈ $5.08 Million |
AU$15.21 Million ≈ $10.76 Million |
-4.71pp |
| 2022-06-30 | 51.92% | AU$12.10 Million ≈ $8.56 Million |
AU$23.31 Million ≈ $16.49 Million |
+13.28pp |
| 2021-06-30 | 38.63% | AU$7.10 Million ≈ $5.02 Million |
AU$18.38 Million ≈ $13.00 Million |
+8.77pp |
| 2020-06-30 | 29.87% | AU$3.56 Million ≈ $2.52 Million |
AU$11.94 Million ≈ $8.45 Million |
-17.21pp |
| 2019-06-30 | 47.08% | AU$7.64 Million ≈ $5.40 Million |
AU$16.22 Million ≈ $11.48 Million |
-7.83pp |
| 2018-06-30 | 54.90% | AU$9.90 Million ≈ $7.00 Million |
AU$18.03 Million ≈ $12.75 Million |
+15.83pp |
| 2017-06-30 | 39.07% | AU$3.99 Million ≈ $2.82 Million |
AU$10.21 Million ≈ $7.22 Million |
+7.98pp |
| 2016-06-30 | 31.09% | AU$4.03 Million ≈ $2.85 Million |
AU$12.95 Million ≈ $9.16 Million |
-- |
About Actinogen Medical Ltd
Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11ß-HSD1 enzyme that achieves target engagement in the brain for the treatment of Alzheimer's disease, major depressive disorder, fragile x syndrome, and other ne… Read more